As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.